Evaluation of the potency of FDA-approved drugs on wild type and mutant SARS-CoV-2 helicase (Nsp13)

dc.contributor.author	Ugurel, Osman Mutluhan
dc.contributor.author	Mutlu, Ozal
dc.contributor.author	Sariyer, Emrah
dc.contributor.author	Kocer, Sinem
dc.contributor.author	Ugurel, Erennur
dc.contributor.author	Inci, Tugba Gul
dc.contributor.author	Ata, Oguz
dc.contributor.author	Turgut-Balik, Dilek
dc.date.accessioned	2021-12-21T08:47:38Z
dc.date.available	2021-12-21T08:47:38Z
dc.date.issued	2020
dc.identifier.issn	0141-8130
dc.identifier.issn	1879-0003
dc.identifier.uri	https://doi.org/10.1016/j.ijbiomac.2020.09.138
dc.identifier.uri	http://dspace.yeniyuzyil.edu.tr:8080/xmlui/handle/20.500.12629/2277
dc.description.abstract	SARS-CoV-2 has caused COVID-19 outbreak with nearly 2 M infected people and over 100K death worldwide, until middle of April 2020. There is no confirmed drug for the treatment of COVID-19 yet. As the disease spread fast and threaten human life, reposition
dc.language.iso	English
dc.publisher	Elsevıer
dc.rights	Bronze, Green Published
dc.title	Evaluation of the potency of FDA-approved drugs on wild type and mutant SARS-CoV-2 helicase (Nsp13)
dc.type	Article
dc.relation.journal	Internatıonal Journal Of Bıologıcal Macromolecules
dc.identifier.startpage	1687
dc.identifier.endpage	1696
dc.identifier.volume	163
dc.identifier.doi	10.1016/j.ijbiomac.2020.09.138
dc.relation.volume	163